Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q4 EPS by 131c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $59.57 -0.55%
Financial Fact:
Loss on sale of fixed assets, net: 0
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Loss on sale of fixed assets, net: 0
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q4 EPS of ($1.92), $1.31 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $240.73 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Sinda Ltd. (SIND) Reports Q3 Loss of $0.10
- People Incorporated (PPLI) Misses Q3 EPS by 896c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
